Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status
Vaccines · 03.08.2026 · 14 (8) · 673
DOI: 10.3390/vaccines14080673 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 03.08.2026. Verfasst von Fani Ladomenou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Medical School, University of Ioannina, 41510 Ioannina, Greece. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory tract infection in early infancy, with the highest burden concentrated in the first months of life. Two immunoprophylactic strategies—maternal RSVpreF vaccination and long-acting monoclonal antibodies—now offer effective early life protection, yet differ in biological mechanisms, operational requirements, and programmatic implications. Maternal vaccination induces high-quality neutralizing antibodies that are transferred transplacentally, providing immediate protection from birth and integrating efficiently into antenatal care platforms. However, its effectiveness is constrained by gestational timing, physiological antibody waning, and reduced protection when vaccination occurs shortly before delivery. Long-acting monoclonal antibodies, including nirsevimab and clesrovimab, bypass maternal immune variability and provide standardized, season-long protection across gestational ages, including preterm infants. Economic evaluations demonstrate that both strategies can be cost-effective, though their relative value depends on local epidemiology, pricing, and coverage patterns. Economic outcomes for monoclonal antibodies and maternal vaccination are highly context-dependent and influenced by regional RSV epidemiology, healthcare utilization, product pricing, and implementation capacity, rather than universally favoring one strategy over the other. Global equity considerations remain critical: disparities in antenatal care access, supply chain fragility, and pricing differentials may widen gaps between high- and low-income countries. Remaining evidence gaps—including long-term safety monitoring, durability of protection, viral evolution, and implementation challenges—underscore the need for continued research and careful integration of these tools into national immunization programs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatrics, Medical School, University of Ioannina, 41510 Ioannina, Greece.
- Department of Paediatrics, Medical School, University of Patras, 26504 Rio, Greece.
ORCID-Profile: Fani Ladomenou, Despoina Gkentzi
Zitieren
APA
Ladomenou, F., Psarra, I. A., & Gkentzi, D. (2026). Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status. Vaccines, 14(8), 673. https://doi.org/10.3390/vaccines14080673
Vancouver
Ladomenou F, Psarra IA, Gkentzi D. Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status. Vaccines. 2026;14(8):673. doi:10.3390/vaccines14080673
BibTeX
@article{Ladomenou2026,
author = {Ladomenou, Fani and Psarra, Ioanna-Andriana and Gkentzi, Despoina},
title = {Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {8},
pages = {673},
doi = {10.3390/vaccines14080673}
}
EUVIMED